Literature DB >> 2393043

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.

J J Gordon1, C A Kauffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2393043     DOI： 10.1016/0002-9343(90)90355-h

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  12 in total

1.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 3.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

4.  Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

Authors:  M E Klepser; E J Ernst; C R Petzold; P Rhomberg; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 7.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

Review 9.  Activity of quinolones against gram-positive cocci: clinical features.

Authors:  H Giamarellou
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 10.  Do we need an intravenous fluoroquinolone?

Authors:  D S Maddix; L Warner
Journal:  West J Med       Date:  1992-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.